Literature DB >> 18413297

Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites.

Timothy Myles1, Lawrence L K Leung.   

Abstract

The cytokine osteopontin (OPN) can be hydrolyzed by thrombin exposing a cryptic alpha(4)beta(1)/alpha(9)beta(1) integrin-binding motif (SVVYGLR), thereby acting as a potent cytokine for cells bearing these activated integrins. We show that purified milk OPN is a substrate for thrombin with a k(cat)/K(m) value of 1.14 x 10(5) m(-1) s(-1). Thrombin cleavage of OPN was inhibited by unsulfated hirugen (IC(50) = 1.2 +/- 0.2 microm), unfractionated heparin (IC(50) = 56.6 +/- 8.4 microg/ml) and low molecular weight (5 kDa) heparin (IC(50) = 31.0 +/- 7.9 microg/ml), indicating the involvement of both anion-binding exosite I (ABE-I) and anion-binding exosite II (ABE-II). Using a thrombin mutant library, we mapped residues important for recognition and cleavage of OPN within ABE-I and ABE-II. A peptide (OPN-(162-197)) was designed spanning the OPN thrombin cleavage site and a hirudin-like C-terminal tail domain. Thrombin cleaved OPN-(162-197) with a specificity constant of k(cat)/K(m) = 1.64 x 10(4) m(-1) s(-1). Representative ABE-I mutants (K65A, H66A, R68A, Y71A, and R73A) showed greatly impaired cleavage, whereas the ABE-II mutants were unaffected, suggesting that ABE-I interacts principally with the hirudin-like OPN domain C-terminal and contiguous to the thrombin cleavage site. Debye-Hückel slopes for milk OPN (-4.1 +/- 1.0) and OPN-(162-197) (-2.4 +/- 0.2) suggest that electrostatic interactions play an important role in thrombin recognition and cleavage of OPN. Thus, OPN is a bona fide substrate for thrombin, and generation of thrombin-cleaved OPN with enhanced pro-inflammatory properties provides another molecular link between coagulation and inflammation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413297      PMCID: PMC2440630          DOI: 10.1074/jbc.M708629200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  An extensive interaction interface between thrombin and factor V is required for factor V activation.

Authors:  T Myles; T H Yun; S W Hall; L L Leung
Journal:  J Biol Chem       Date:  2001-04-18       Impact factor: 5.157

2.  Electrostatic steering and ionic tethering in enzyme-ligand binding: insights from simulations.

Authors:  R C Wade; R R Gabdoulline; S K Lüdemann; V Lounnas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

4.  Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.

Authors:  D R Senger; C A Perruzzi
Journal:  Biochim Biophys Acta       Date:  1996-11-08

5.  Molecular mapping of the thrombin-heparin cofactor II complex.

Authors:  Yolanda M Fortenberry; Herbert C Whinna; Holly R Gentry; Timothy Myles; Lawrence L K Leung; Frank C Church
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

Review 6.  Control of osteopontin signaling and function by post-translational phosphorylation and protein folding.

Authors:  Christian C Kazanecki; Dana J Uzwiak; David T Denhardt
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

7.  The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.

Authors:  W Bode; D Turk; A Karshikov
Journal:  Protein Sci       Date:  1992-04       Impact factor: 6.725

8.  The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.

Authors:  L Liaw; M P Skinner; E W Raines; R Ross; D A Cheresh; S M Schwartz; C M Giachelli
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

9.  Essential thrombin residues for inhibition by protein C inhibitor with the cofactors heparin and thrombomodulin.

Authors:  Y M Fortenberry; H C Whinna; S T Cooper; T Myles; L L K Leung; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

10.  Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.

Authors:  M Ishijima; S R Rittling; T Yamashita; K Tsuji; H Kurosawa; A Nifuji; D T Denhardt; M Noda
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  14 in total

Review 1.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 2.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

3.  The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.

Authors:  Matthew J Flick; Anil K Chauhan; Malinda Frederick; Kathryn E Talmage; Keith W Kombrinck; Whitney Miller; Eric S Mullins; Joseph S Palumbo; Xunzhen Zheng; Naomi L Esmon; Charles T Esmon; Sherry Thornton; Ann Becker; Leslie A Pelc; Enrico Di Cera; Denisa D Wagner; Jay L Degen
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

4.  Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke.

Authors:  Anne Ladwig; Rebecca Rogall; Jörg Hucklenbroich; Antje Willuweit; Michael Schoeneck; Karl-Josef Langen; Gereon R Fink; M Adele Rueger; Michael Schroeter
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-28       Impact factor: 4.147

5.  Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.

Authors:  Yasuto Yamaguchi; Zhifei Shao; Shadi Sharif; Xiao-Yan Du; Timothy Myles; Milton Merchant; Griffith Harsh; Michael Glantz; Lawrence Recht; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

Review 6.  Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).

Authors:  Lawrence L K Leung; Timothy Myles; Toshihiko Nishimura; Jason J Song; William H Robinson
Journal:  Mol Immunol       Date:  2008-08-15       Impact factor: 4.407

7.  Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis.

Authors:  Shadi A Sharif; Xiaoyan Du; Timothy Myles; Jason J Song; Elizabeth Price; David M Lee; Stuart B Goodman; Mariko Nagashima; John Morser; William H Robinson; Lawrence L K Leung
Journal:  Arthritis Rheum       Date:  2009-10

8.  Thrombin cleavage of osteopontin initiates osteopontin's tumor-promoting activity.

Authors:  Sameera Peraramelli; Qi Zhou; Qin Zhou; Bettina Wanko; Lei Zhao; Toshihiko Nishimura; Thomas H Leung; Seiya Mizuno; Mamoru Ito; Timothy Myles; Thomas M Stulnig; John Morser; Lawrence L K Leung
Journal:  J Thromb Haemost       Date:  2022-02-16       Impact factor: 16.036

9.  Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44.

Authors:  Gulimirerouzi Fnu; Palak Agrawal; Gopal C Kundu; Georg F Weber
Journal:  Biomolecules       Date:  2021-05-30

10.  Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets.

Authors:  Xiao-Yan Du; Brian A Zabel; Timothy Myles; Samantha J Allen; Tracy M Handel; Peter P Lee; Eugene C Butcher; Lawrence L Leung
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.